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Abstract: The incidence of canine mammary carcinoma varies with age, breed, and spay status, being
among the main tumors appearing in intact female dogs. Thirty-six canine mammary carcinoma
patients received injections of canine interferon-β (cIFN-β) and HSV-thymidine kinase/ganciclovir
(HSV-tk/GCV) carrying lipoplexes, into the tumor bed, immediately after surgery. Next, they started
periodic subcutaneous injections of lipoplexes carrying a human granulocyte-macrophage colony
stimulating factor and interleukin-2 mixed with allogeneic mammary carcinoma extracts. This combined
strategy was safe and well tolerated. In addition, only two out of 26 patients treated with complete
surgery developed a local relapse, and 0 out of 29 stage II and III patients displayed distant metastases,
suggesting both local and systemic antitumor activities. The most encouraging result was the long
survival times: 22 > 1 year (where 13 > 2 and 4 > 3 years), while maintaining a good quality of life.
The preliminary results in five patients presenting with local disease, an additional HSV-tk/GCV
plus cIFN-β gene treatment induced local antitumor activity, evidenced by four objective responses
(one complete, three partial) and one stable disease. This successful outcome supports further studies to
validate this approach not only for canine veterinary patients, but also for translation to human patients.
Keywords: IL-2; GM-CSF; HSV-tk; IFN-β; canine mammary carcinoma; cancer vaccine; lipofection;
DMRIE; gene therapy
1. Introduction
Canine mammary carcinomas (CMCs) are among the most prevalent tumors in intact female
dogs [1]. Even though an ovariectomy is an efficient preventive action, this is not a common practice
in every geographical region. Among the CMCs, there are a variety of subtypes with different
histologies [2]. Because of the similarities with human breast carcinoma, CMCs have been proposed
as models for studying human carcinogenesis [3] and prognostic factors [4,5]. Lately, there were
important advances in the understanding of the clinically relevant genetic and molecular pathways
involved, driving cell proliferation, apoptosis and DNA repair, metastasis, and the interactions of
tumor cells with other non-tumor cells in CMCs [6–8].
CMCs have less treatment alternatives in comparison with human breast cancer; many new
therapies used for human patients were not validated for companion animals, and most of them
would be too expensive and therefore prohibitive for owners. Therefore, in the veterinary oncology
context, the development of new simple and affordable approaches is compelling. Along this way,
cancer immunogene therapy is an especially suitable and fast expanding field that was reasonably
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explored for malignant melanoma and other kinds of canine spontaneous tumors [9,10]. It is worth
mentioning that three small trials of immunogene therapy for mammary carcinoma have been reported.
Two of them used IL-12 electrogene therapy [11,12] and the another used a p62 DNA vaccine [13].
Our laboratory has developed efficiently combined gene therapies as surgery adjuvants for canine
melanoma [14], soft tissue sarcomas [15], and osteosarcoma [16]. The treatments combined the local
antiproliferative activity of the herpes simplex virus thymidine kinase (HSVtk) suicide gene and canine
interferon-β (cIFNβ) gene therapy with the systemic action generated by a subcutaneous vaccine made
from formolized tumor extracts and slow cytokine releasing biological systems. The lipoplexes carrying
human interleukin-2 (hIL-2) and human granulocyte-macrophage colony-stimulating factor (hGM-CSF)
were effective as immune enhancers with the canine melanoma vaccine, and their components proved
to be especially suitable for long term storage and delivery [14]. Taking into account our previous
experience with immunogene therapy, we are presenting a similar approach for treating CMCs,
in a new study testing the feasibility and safety of the combination of local suicide plus interferon-β,
and a cytokine enhanced tumor vaccine.
2. Materials and Methods
2.1. Plasmids
The same psCMV plasmid backbone was used as a carrier of all of the genes. Herpes simplex
thymidine kinase (psCMVtk), canine interferon-β (psCMVcIFNβ), human interleukin-2 (psCMVhIL2),
and human granulocyte-macrophage colony-stimulating factor (psCMVhGM-CSF) genes were
subcloned, amplified, purified, and diluted to a final concentration of 2.0 mg/mL in sterile phosphate-
buffered saline, as described [14].
2.2. Liposomes Preparation and Local Lipoplexes Injection
The liposomes were made as previously reported [14]. They were composed of equimolar
amounts of DMRIE (1,2-dimyristyl oxypropyl-3-dimethyl-hydroxyethylammonium bromide) and
DOPE (1,2-dioleoyl-sn-glycero-3-phosphatidyl ethanolamine). The lipoplexes were assembled by
mixing liposomes and plasmid DNAs (1:2 v:v) at room temperature for 10 min. Subsequently, 5 mg
ganciclovir (GCV)/mg DNA was added and the mixture was injected intra- and/or peri-tumorally
into multiple sites, as described in Section 2.5.
2.3. Tumor Vaccines Preparation
Surgically removed tumors were processed as previously described [17]. Aliquots of 0.05–0.10 mL
of insoluble pellets of homogenized tumors were stored at −80 ◦C until used. No microbial cultivable
contamination was found in the tumor preparations. The analyses for endotoxin presence (≤1 EU /µg
protein) were performed using the Limulus Amebocyte Lysate assay. Autologous or allogeneic tumor
cells prepared in 0.25 mL were mixed with 0.75 mL of lipoplexes carrying 0.5 mg psCMVhIL2 plus
0.5 mg psCMVhGM-CSF, just before subcutaneous injection.
2.4. Patients
Inclusion criteria: Female dogs with a confirmed histopathological diagnostic of malignant
mammary carcinoma and that were free of severe underlying systemic illnesses were evaluated for
being entered into the study. There were no restrictions on the disease stage or burden. The tumors
were staged according to the World Health Organization (WHO), as previously described [17],
as follows: stage II, for primary tumors from 2 to 4 cm diameter with negative proximal lymph
nodes; stage III, for tumors ≥4 cm diameter without metastasis or any size of primary tumor
with lymph node metastasis; or stage IV, for distant metastatic disease. The staging methods
included physical examination, thoracic radiography, abdominal echography, complete blood count,
serum biochemistry profile, urinalysis, and coagulation profile. All of the patients entered the study
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with a modified Eastern Cooperative Oncology Group (ECOG) performance status of <2 (normal
activity or decreased activity from pre-disease status), as previously defined [18]. Exclusion criteria:
alkaline phosphatase ≥3× normal; hepatic transaminases ≥3× normal; total bilirubin ≥2× normal;
creatinine ≥2× normal; <2000 neutrophils/µL; <100,000 platelets/µL; hematocrit <25%; and evidence
of preexisting non controlled, non tumor-related cardiovascular, pulmonary, or immune disease.
Neither chemotherapy nor any other potentially antitumor or immunosuppressive medication was
administered to the dogs in the previous four weeks or during the study. Standard antibiotics,
non steroid anti-inflammatory, and/or analgesic medication were used when needed. All of the
dogs’ owners signed the corresponding written informed consent for this experimental treatment.
The surgery procedures and clinical follow-up were performed by qualified attending veterinary
professionals, following the laws and regulations of our country (Argentina). All of the scientific and
ethical issues related to the veterinary clinical trial were evaluated and approved by the appropriate
committee of the granting agency (ANPCYT, Buenos Aires, Argentina).
2.5. Study Design and Treatment
Three veterinary care centers recruited patients and took part in this prospective study. At the time
of surgery, the patients were assigned, taking into account whether they were subjected to complete
(CS) or partial (cytoreductive) surgery (PS).
Figures 1 and 2 display the general scheme of the treatment and the CONSORT chart, respectively [19].
The patients getting the combined treatment (n = 36) were subjected to partial (PS, n = 10) or complete
surgery (removal of all detectable tumor burden followed by confirmation of clean surgical margins in
the histopathological report) (CS, n = 26), as described [14]. The surgical margin of the cavity produced
by the tumor removal was injected with cIFNβ and suicide gene carrying lipoplexes (1 to 4 mg DNA
of each) co-delivered with GCV (5–20 mg), according to the tumor bed (about 0.1 mg DNA/cm2 of
surgical margin). The injections were uniformly spread at multiple locations in the surrounding areas
and/or in the remaining tumor tissue. Starting at surgery, the patients were treated once a week
for five weeks with a subcutaneous vaccine composed by allogeneic formolized tumor cell extracts
(containing about 0.05–0.10 mL of insoluble pellet) and lipoplexes carrying the genes of hIL-2 and
hGM-CSF (0.5 mg DNA of each cytokine). After that, the patients received a subcutaneous vaccine
with decreasing frequency five times (5×) every other week, three times monthly, three times monthly,
every three months, and lastly, every six months until relapse or death.
In a parallel exploratory group, at a local recurrence (n = 4) or local disease progression (n = 1),
patients were subjected to weekly intratumoral injections of cIFNβ and suicide gene carrying lipoplexes
co-delivered with GCV, as described above. They also restarted the weekly subcutaneous vaccine
schedule. The follow-up lasted until the patients’ death or the end of the study. For the sake of
simplicity, a local relapse was considered as a recurrence in the same place, invasion of surrounding
tissue, and/or regional metastasis (including very proximal lymph nodes). As reported in a previous
study [15], the tumor responses were evaluated following WHO criteria.
As previously described [17], the periodic clinical evaluations were performed every treatment
day and were completed by a monthly or bimonthly clinical laboratory analysis. Thoracic radiographs
and abdominal echographs were done before treatment, and every month, or trimester, according to the
patients’ response, and at longer intervals (six months) in long-term surviving animals. The patients
subjected to a second local treatment also restarted the (i) periodic clinical evaluations every treatment
day, and the (ii) thoracic radiographies and abdominal echographies every month.
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Figure 1. Diagram of the combined gene therapy as a surgery adjuvant. Figure 1. Diagram of the combined gene therapy as a surgery adjuvant.
The quality of life was assessed by a questionnaire completed by the owner before every treatment
session, as described [17].
The following endpoints were determined: overall survival (OS), survival to CMC (MS),
recurrence-free survival (RFS), metastasis-free survival (MFS), and disease-free survival (DFS). OS and
MS were defined as the periods of time between first treatment day and death due to any cause or to
CMC, respectively. If death was not observed during the study, the data on OS and MS were censored
at the last date the patient was known to be alive. RFS, MFS, and DFS were defined as the interval
from the initiation of the treatment to recurrence, metastasis, or the first detection of any of them,
respectively. The dogs were censored from the analysis if they were disease-free at the time of the last
follow-up or lost to follow-up.
Statistical studies of survival data were made by a Kaplan-Meier analysis, where y = the curves
were compared by a Log-rank test, while response data were analyzed by 2-tail Fisher’s Exact test.
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3. Results and Discussion
A detail d d scription of the treatment scheme appears in the Materials and Methods section,
in Figure 1, and a CONSORT chart [19] of the trial is shown in Figure 2.
The patients’ median age at recruitment was 12 (5–15) years (Table 1), and the mean age
11.28 ± 0.35 years. The main breeds were the Cocker spaniel (19.4%), German shepherd (11.1%),
Rottweiler (5.6%), and Schnauzer (5.6). The majority of the patients belonged to mixed breeds (33.3%)
and other diverse breeds (25.0%).
Table 1. Patient demographics, disease stages at study entry, and survival times.
# Breed Initial Age (Years) Stage Surgery Type Local Relapse Cause of Death Survival (Days)
1 Schnauzer 9 II Complete No Alive >306
2 Cocker spani l 10 II Complete No Alive >491
3 Bichon frisé 12 II Complete No Alive >1498
4 Mixed breed 14 II Complete Yes Unrelated 358
5 Cocker spaniel 13 II Complete No Unrelated 422
6 Beagle 11 II Complete No Unrelated 449
7 Mixed breed 13 II Complete No Unrelated 496
8 Doberman pinscher 13 II Complete No Discontinued >580
9 Breton 13 II Complete No Unrelated 788
10 Siberian husky 13 II Complete No Discontinued >1163
11 Mixed breed 12 II Complete No Unrelated 1033
12 Mixed breed 9 III Complete No Alive >273
13 Pointer 11 III Complete No Alive >834
14 Cocker spaniel 12 III Complete No Alive >935
15 Boston terrier 13 III Complete No Alive >991
16 Cocker spaniel 13 III Complete Yes Related 211
17 Mixed breed 10 III Partial * Yes Related * 241
18 German shepherd 14 III Partial * Yes Related 330
19 Mixed breed 11 III Partial * Yes Related 352
20 Mixed breed 14 III Complete No Discontinued >384
21 Brittany 11 III Complete No Discontinued >575
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Table 1. Cont.
# Breed Initial Age (Years) Stage Surgery Type Local Relapse Cause of Death Survival (Days)
22 Mixed breed 9 III Complete No Unrelated 594
23 Cocker spaniel 12 III Partial * Yes Related 708
24 Cocker spaniel 12 III Complete No Discontinued >775
25 Schnauzer 11 III Complete No Unrelated 869
26 Rottweiler 13 III Partial * Yes Unrelated 876
27 German shepherd 8 III Partial * Yes Related 932
28 Mixed breed 7 III Complete No Unrelated 1234
29 Cocker spaniel 10 III Complete No Discontinued >1345
30 German shepherd 11 IV Complete No Related 99
31 Mixed breed 5 IV Complete No Related 117
32 German shepherd 6 IV Partial * Yes Related * 127
33 Mixed breed 15 IV Partial * Yes Related * 170
34 Rottweiler 13 IV Partial * Yes Unrelated 175
35 Mixed breed 11 IV Complete No Related * 183
36 German shepherd 12 IV Partial * Yes Related * 205
* PS patients were considered as relapsing at time 0 after surgery. Surgery: CS—complete; PS—partial.
The histological types found in this study were considerably diverse and a proportion of the
patients presented with an advanced clinical staging, which negatively impacts the overall survival.
The main types were tubulopapillary (22.2%), solid (19.4%), tubular (16.7%), ductal (11.1%), complex
(8.3%), anaplastic (5.6%), and other diverse types (16.7%). Every patient was staged as follows: Most of
them were at stage III (50%) or stage II (31%). Nearly 19% of the patients had lung metastases (stage IV)
when incorporated to the trial.
Figure 3 displays the Kaplan–Meier plots obtained from survival data. The median overall survival
of the whole group was 708 days, but if only the deaths related to CMC were considered, it was >1498
(Figure 3a and Table 2). Nevertheless, the survival curves were not significantly different.
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Figure 3. Kaplan–Meier analysis of the overall (a–c) and disease-free (d) survival. (a) All of the
patients were considered as a single group. (b) The patients were grouped by the initial disease
stage. (c) The patients subject tial (PS) and compl te (CS) surgery were differentially grouped.
(d)Disease-fre urvival. The patients wer treate follow-ups wer performe , as described
in the Materials and Methods. Abbreviations: OS overall survival to any cause (death related or
unrelated to CMC); MS—overall survival to CMC (death related to CMC); DFS—disease-free survival;
RFS—recurrence-free survival; MFS—metastasis-free survival.
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Table 2. Median overall survivals obtained from Kaplan-Meier data (Figure 3a,b).
Survival n Overall (to Any Cause): OS Overall (to CMC): MS OS vs. MS
All stages 36 708 (99–498) >1498 (99–1498) NS
Stage II 11 788 (306–1498) >1498 (306–1498) NS
Stage III 18 876 (167–1345) 932(167–1345) NS
Stage IV 7 170 (99–205) 170 (99–205) NS
Stage II vs. Stage III NS p < 0.0423
-Stage II vs. Stage IV p < 0.0001 p < 0.0001
Stage III vs. Stage IV p < 0.0001 p < 0.0001
Abbreviations: OS—overall survival to any cause; MS—overall survival to CMC; CMC—canine mammary
carcinoma; NS—not significant. Patients were clinically evaluated and treated as described in Materials and
Methods. p-values were calculated by Log-rank test for Kaplan–Meier analysis.
The median survivals appeared to be related to the CMC stage at the beginning of the treatment
(Figure 3b and Table 2). For both stages II and III, the median survivals were significantly higher than
the corresponding stage IV values.
The disease stage at the beginning of the treatment significantly impacted the quality of the
surgical procedure. Partial surgery was performed only when necessary, in the patients with a poorer
prognosis at higher disease stages, stages III (six patients) and IV (five patients). Therefore, the overall
median overall survival of the latest group was significantly lower compared with the complete
surgery group (241 vs. 876 days, Figure 3c and Table 3, respectively). This difference was higher when
only the deaths related to CMC were considered (330 vs. >1498 days).
The metastasis- (MFS), recurrence- (RFS), and disease-free (DFS) survivals did not reach the
median during the study, being >1498 days for the three parameters (Figure 3d and Table 3). It is
noteworthy that none of the stage II and III patients developed distant metastases during or after
treatment. Only one (out of 11) stage II, one stage III (out of 12), and 0 stage IV (out of 3) patients that
were subjected to complete surgery displayed local recurrence.
It is worth mentioning that two stage II CMC patients that were not included in the study were
successfully treated for canine mucosal melanoma by us, before being treated for CMC. A combination
of suicide and cytokine gene therapies had been applied, as described [14]. These long-term melanoma
and mammary carcinoma survivors displayed total survivals >1766 and >2595 days, where the CMC
survivals were >1448 and >1797, respectively. This fact supports the highly specific nature of the
subcutaneous tumor vaccine that is the only difference between the two treatments, as well as the
efficacy and safety of the treatment. Both patients are still alive and demonstrating a good quality of life.
Table 3. Median overall and disease-free survivals obtained from Kaplan–Meier data (Figure 3c).
SURVIVAL (Days)
GT (n = 36) CS vs. PS
CS+GT (n = 26) PS+GT (n = 10) (p<)
Overall (any cause): OS 876 (99–498) 241 (127–932) 0.0006
Overall (to CMC): MS >1498 (99–1498) 330 (127–932) 0.0001
Metastasis-free Recurrence-free Disease-free
Survival (days) >1498 (167–1498) >1498 (99–1498) >1498(99–1498)
Abbreviations: CS—complete surgery; GT—gene therapy combined treatment; NS—no significant; PS—partial
surgery; DFS—disease-free survival; RFS—recurrence-free survival; MFS—metastasis-free survival. The patients
were clinically evaluated and treated as described in Materials and Methods. The p-values were calculated by a
Log-rank test for the Kaplan–Meier analysis. The stage IV patients starting with metastasis (n = 8) were not included
in MFS and DFS, and those subjected to PS (n = 11) were not included in RFS and DFS calculations.
Table 4 shows that most of the complete surgery treated patients (81%) were free of disease at
the end of the study (this included the seven still alive patients), about 92% without local disease and
about 88% without systemic disease (metastasis).
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Table 4. Disease status at the end of the study and causes of death.
Patients
GT (n = 36)
CS+GT (n = 26) PS+GT (n = 10) CS+GT vs. PS+GT
n (%) n (%) p<
Local disease-free 24 (92.3) 0 * (0)
0.0001
With local disease 2 (7.7) 10 * (100)
Metastasis-free 23 (88.5) 6 (60.0)
NS
With metastasis 3 (11.5) 4 (40.0)
Disease-free 21 (80.8) 0 * (0)
0.0001
With disease 5 (19.2) 10 (100)
Alive 7 (26.9) 0 (0)
NDDead 13 (50.0) 10 (100)
Dropped-out 6 (23.1) 0 (0)
Death n (%) n (%) p<
CMC-related 4 (30.8) 8 (80.0)
0.0361
CMC-unrelated 9 (69.2) 2 (20.0)
Abbreviations: CS—complete surgery; GT—gene therapy combined treatment; ND—not determined;
NS—not significant; PS—partial surgery. The patients were clinically evaluated and treated as described in
Materials and Methods. p-values were calculated by 2-tail Fisher’s Exact test. * PS patients were considered
as relapsing at time 0 after surgery.
As discussed above, the initial stage of the disease had a strong influence on the outcome.
There was a significant difference between the causes of death for the CS and PS patients. While only
31% of the complete surgery patients died because of CMC progression, 80% of the partial surgery
patients did so (Table 4). This was a very encouraging outcome that supports further studies on
this subject.
Preliminary data regarding a rescue scheme for the locally relapsing patients are shown in
Table 5. A second local treatment of intratumoral lipoplexes carrying suicide and cIFNβ gene injections
was offered to five patients (treated as described in Figure 1, but not included in the main trial,
Table 1),to four when recurrence appeared after complete surgery and to one after a partial surgery.
This action resulted in the following tumor control for the five treated patients: one complete response
(CR), three partial responses (PR), and one stable disease (SD). Therefore, in the case of local recurrence
or incomplete surgery, additional local gene therapy is feasible. More data are necessary to validate
the efficacy this supplementary treatment.
The patients’ quality of life estimation was performed as described [14]. During the treatment,
there was a high rate of re-establishment to the pre-disease situation of activity (72%), alert state (64%),
appetite (72%), disposition (69%), and general welfare (75%).
The combined gene therapy treatment was safe, not allergenic, and could be applied numerous
times. Rarely, some patients displayed minor adverse side effects that can be classified as grade ≤1
following the VCOG-CTCAE criteria [20]. Adverse effects included induration at the injection sites
that resolved after 1–2 weeks (2/36, 5.5%), and a 1–2 day reduction of patient’s activity (5/36, 13.9%),
after subcutaneous vaccination. The treatment did not produce any significant changes in the clinical
and hematological parameters, local or systemic toxicity, and fever or organic dysfunction.
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Table 5. Outcome of an additional local treatment for local relapse.
# Breed Initial Age(Years) Stage
Surgery
Type
Local
Relapse
Response to
Additional Local GT
Cause of
Death
Survival
(Days)
1 Cocker spaniel 8 II CS Yes PR Alive >2263
2 German shepherd 8 II CS Yes PR Related 325
3 Mixed breed 15 II CS Yes SD Related 365
4 Golden retriever 9 III CS Yes CR Unrelated 1263
5 Mixed breed 15 IV PS * Yes PR Related 167
* PS patients were considered as relapsing at time 0 after surgery. Responses: CR—complete; PR—partial; SD—stable
disease. Surgery: CS—complete; PS—partial. Gene therapy—GT. After being treated as described in Figure 1, all of
these patients (p) were subjected to additional cycles of GT (HSVtk/GCV and cIFNβ genes) when they had locally
relapsed (p1–p4), or immediately after surgery (p5), as described in Materials and Methods.
4. Conclusions
Based on our previous experience with canine melanoma [14], we proposed a similar scheme of
this immunogene therapy approach for a new study in canine mammary carcinoma. As a surgery
adjuvant, the treatment comprised a single post-surgical application of local cIFNβ plus suicide gene
therapy, supplemented by the periodic subcutaneous allogeneic genetic vaccine. This vaccine was
composed of whole tumor formolized extracts and lipoplexes carrying the hIL-2 and hGM-CSF genes.
After more than five years of follow up, we conclude that the proposed treatment applied after
surgical excision of the tumor showed a high level of safety, even in long-term surviving patients that
were periodically treated for many years.
It is interesting to compare our results with the already published data. Among the few published
materials regarding the overall survival to CMC after the surgical removal of tumors, two studies
provided valuable data. In the first article, stage II and III patients displayed median overall survivals
of 579 and 252 days respectively [21]. In the second article stage II patients displayed a median overall
survival of 406 days [22]. Beyond the actual differences in treatments made in different countries by
different professionals at different times, it is worth noting that our treated canine patients displayed a
median OS that largely exceeded such results, 788 days for stage II and 876 days for stage III.
As far as we know, the present trial is the largest veterinary cancer immunogene therapy study
for canine mammary carcinoma reported to date. The high simplicity of the elements involved in
this approach and the promising outcome reported here, encourage further trials in order to ascertain
the efficacy of this approach, compared to a control group subjected to the best available approved
treatment. In addition, a new larger study could provide a preclinical proof of concept and long
term safety data for the eventual translation of a similar methodology to clinical trials for human
breast cancer.
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